Comparison of the Quantitative CT Imaging Biomarkers of Idiopathic Pulmonary Fibrosis at Baseline and Early Change with an Interval of 7Months

Academic Radiology

Volumn 22, Issue 1, 2015, Pages 70-80

  Kim, Hyun J ^a,b,c   Brown, Matthew S ^a,b   Chong, Daniel ^a,b   Gjertson, David W ^b,c   Lu, Peiyun ^a,b   Kim, Hak J ^b   Coy, Heidi ^a,b   Goldin, Jonathan G ^a,b  

^a Center for Computer Vision and Imaging Biomarkers   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CAD; ILD; Imaging biomarkers; IPF; Quantitative lung fibrosis; Texture

Indexed keywords

BIOLOGICAL MARKER; CARBON MONOXIDE;

ARTICLE; CLASSIFICATION ALGORITHM; CLASSIFIER; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; HISTOGRAM; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; TIME; COMPUTER ASSISTED DIAGNOSIS; DISEASE COURSE; EARLY DIAGNOSIS; IMAGE QUALITY; LONGITUDINAL STUDY; PROCEDURES; RADIOGRAPHY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LONGITUDINAL STUDIES; MALE; RADIOGRAPHIC IMAGE ENHANCEMENT; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84919461263     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2014.08.004     Document Type: Article

References (43)

1. Schwartz D.A., Helmers R.A., Galvin J.R., et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994, 149:450-454.
2. Raghu G., Weycker D., Edelsberg J., et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 74:810-816.
3. Olson A.L., Swigris J. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin Chest Med 2012, 33:41-50.
4. GarcÃa-Sancho C., BuendÃa-RoldÃn I., FernÃndez-Plata M.R., et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 2001, 105:1902-1907.
5. King T.E., Schwarz M.I., Brown K., et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001, 164:1025-1032.
6. Ley B., Ryerson C.J., Vittinghoff E., et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012, 156:684-691.
7. du Bois R.M., Weycker D., Albera C., et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:459-466.
8. Wells A.U., Desai S.R., Rubens M.B., et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003, 167:962-969.
9. Latsi P.I., du Bois R.M., Nicholson A.G., et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531-537.
10. Raghu G., Collard H.R., Egan J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
11. Hodnett P.A., Naidich D.P. Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med 2013, 188:141-149.
12. Raghu G., Collard H.R., Anstrom K.J., et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012, 185:1044-1048.
13. Cottin V. Interstitial lung disease. Eur Respir Rev 2013, 22:26-32.
14. Woodcock H.V., Molyneaux P.L., Maher T.M. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther 2013, 7:503-510.
15. Adamali H.I., Maher T.M. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther 2012, 6:261-272.
16. Loomis-King H., Flaherty K.R., Moore B.B. Pathogenesis, current treatment and future direction for idiopathic pulmonary fibrosis. Curr Opin Pharmacol 2013, 13:377-385.
17. O'Connell O.J., Kennedy M.P., Henry M.T. Idiopathic pulmonary fibrosis: treatment update. Adv Ther 2011, 28:986-999.
18. Mahendran S., Sethi T. Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach?. QJM 2012, 105:929-934.
19. Maher T.M. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev 2013, 22:148-152.
20. Title of Advisory Committee document 2010, US Food and Drug Administration (FDA), FDA, Maryland, Available at:, Accessed April 18, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf.
21. Kotloff R.M., Thabut G. Lung Transplantation. Am J Respir Crit Care Med 2011, 184:159-171.
22. Best A.C., Lynch A.M., Bozic C.M., et al. Quantitative CT indexes in idiopathic pulmonary fibrosis: relationship with physiologic impairment. Radiology 2003, 228:407-414.
23. Lynch D.A. Quantitative CT of fibrotic interstitial lung disease. Chest 2007, 131:643-644.
24. Camiciottoli G., Orlandi I., Bartolucci M., et al. Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life. Chest 2007, 131:672-681.
25. Best A.C., Meng J., Lynch A.M., et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 2008, 246:935-940.
26. Uppaluri R., Hoffman E.A., Sonka M., et al. Computer recognition of regional lung disease patterns. Am J Respir Crit Care Med 1999, 160:648-654.
27. Chabat F., Yang G.Z., Hansell D.M. Obstructive lung diseases: texture classification for differentiation at CT. Radiology 2003, 228:871-877.
28. Zavaletta V.A., Bartholmai B.J., Robb R.A. High resolution multidetector CT-aided tissue analysis and quantification of lung fibrosis. Acad Radiol 2007, 14:772-787.
29. Kim H.G., Tashkin D.P., Clements P.J., et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol 2010, 28(5 Suppl 62):S26-S35.
30. Kim H.J., Li G., Gjertson D., et al. Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol 2008, 15:1004-1016.
31. Maldonado F., Moua T., Rajagopalan S., et al. Automated quantification of radiologic patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J 2013, 43:204-212.
32. Bartholmai B.J., Raghunath S., Karwoski R.A., et al. Quantitative computed tomography imaging of interstitial lung diseases. J Thorac Imaging 2013, 28:298-307.
33. Kim H.J., Brown M.S., Elashoff R., et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 2011, 21:2455-2465.
34. Brown M.S., Kim H.J., Abtin F., et al. Reproducibility of lung and lobar volume measurements using computed tomography. Acad Radiol 2010, 17:316-322.
35. Cramer D. Fundamental statistics for social research 1997, 89-90. Routledge, New York NY. 1st ed.
36. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
37. Temple R.J. A regulatory authority's opinion about surrogate endpoints. Clinical measurement in drug evaluation 1995, 1-22. John Wiley, New York. W.S. Nimmo, G.T. Tucker (Eds.).
38. Fan J., Li J. Variable selection via nonconcave penalized likelihood and its oracle properties. J Am Stat Assoc 2001, 96:1348-1360.
39. Vapnik V.N. The nature of statistical learning theory 1999, 138-160. Springer, New York, NY. 2nd ed.
40. Gay S.E., Kazerooni E.A., Toews G.B., et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998, 157:1063-1072.
41. Tashkin D.P., Elashoff R., Clements P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
42. du Bois R.M., Weycker D., Albera C., et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011, 184:1382-1389.
43. Wells A.U. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax 2013, 68:309-310.